UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Abstract C117: Preclinical characterization of allogeneic CAR γδ T Cell therapy for prostate cancer targeting a novel dimeric epitope on PSMA

Molecular cancer therapeutics, 2023-12, Vol.22 (12_Supplement), p.C117-C117

2023

Volltextzugriff (PDF)

Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

Blood, 2023-11, Vol.142 (Supplement 1), p.3478-3478

2023

Volltextzugriff (PDF)

684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A777-A777

2023

Volltextzugriff (PDF)

265 ADI-925: an allogeneic off-the-shelf chimeric adapter (CAd) γδ T cell therapy targeting NKG2D ligand-expressing cancers

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A305-A305

2023

Volltextzugriff (PDF)

246 Disruption of the cytokine signaling checkpoint CIS enhances serial-killing and anti-tumor activity of CAR-engineered γδ T cells

Journal for immunotherapy of cancer, 2023-11, Vol.11 (Suppl 1), p.A285-A285

2023

Volltextzugriff (PDF)

Correction: Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

The Journal of experimental medicine, 2022-11, Vol.219 (11)

2022

Volltextzugriff (PDF)

203 Preclinical discovery and characterization of allogeneic anti-PSMA γδ CAR T therapy for prostate cancer

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A216-A216

2022

Volltextzugriff (PDF)

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Clinical & translational immunology, 2022, Vol.11 (2), p.e1373-n/a

2022

Volltextzugriff (PDF)

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Journal for immunotherapy of cancer, 2021-12, Vol.9 (12), p.e003441

2021

Volltextzugriff (PDF)

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis

Multiple sclerosis journal - experimental, translational and clinical, 2021-04, Vol.7 (2), p.20552173211019772-20552173211019772

2021

Volltextzugriff (PDF)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)

Trends in molecular medicine, 2021-04, Vol.27 (4), p.410-411

2021

Volltextzugriff (PDF)

Comprehensive Activation Profiling of Tabelecleucel, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Immunotherapy

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S189-S190

2021

Volltextzugriff (PDF)

ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S186-S187

2021

Volltextzugriff (PDF)

A Sensitive and Precise Universal Surveillance Solution for Pharmacokinetic Monitoring of Off-the-Shelf Cell Therapies

Transplantation and cellular therapy, 2021-03, Vol.27 (3), p.S187

2021

Volltextzugriff (PDF)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: Trends in Molecular Medicine, 26:3 p:296-310, 2020

Trends in molecular medicine, 2021-02, Vol.27 (4), p.410-411

2021

Volltextzugriff (PDF)

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma

Clinical cancer research, 2020-11, Vol.26 (22), p.6028-6038

2020

Volltextzugriff (PDF)

ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing

Blood, 2020-11, Vol.136 (Supplement 1), p.9-9

2020

Volltextzugriff (PDF)

98 ATA3271: an armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors

Journal for immunotherapy of cancer, 2020-11, Vol.8 (Suppl 3), p.A61-A62

2020

Volltextzugriff (PDF)

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

JCI insight, 2020-10, Vol.5 (20)

2020

Volltextzugriff (PDF)

Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

The Journal of experimental medicine, 2020-10, Vol.217 (10)

2020

Volltextzugriff (PDF)

Cover Image

Advances in cell and gene therapy, 2020-07, Vol.3 (3)

2020

Volltextzugriff (PDF)

Toward “off‐the‐shelf” allogeneic CAR T cells

Advances in cell and gene therapy, 2020-07, Vol.3 (3), p.n/a

2020

Volltextzugriff (PDF)

Transcriptional Landscape and TCR Diversity of ATA188, a Pre-manufactured, Allogeneic Epstein-Barr Virus-specific T-cell Immunotherapy for Patients with Multiple Sclerosis (MS) (4397)

Neurology, 2020-04, Vol.94 (15_supplement)

2020

Volltextzugriff (PDF)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies

Trends in molecular medicine, 2020-03, Vol.26 (3), p.296-310

2020

Volltextzugriff (PDF)

1 – 25 von 68

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(65)
Mit Volltextzugriff
(63)

Publikationsform

Artikel
(67)
Dissertationen
(1)

Sprache

Englisch
(68)

Erscheinungsjahr

n.n

Thema

Science & Technology
(26)
Life Sciences & Biomedicine
(24)
Humans
(17)
Animals
(14)
Mice
(13)
Oncology
(12)
Lymphocytes
(9)
Cell Line, Tumor
(8)
Immunotherapy
(8)
Xenograft Model Antitumor Assays
(8)
Antigens
(6)
Female
(6)
Medicine, Research & Experimental
(6)
Research & Experimental Medicine
(6)
Antineoplastic Agents - Pharmacology
(5)
Male
(5)
Aged
(4)
Cell Biology
(4)
Cell Proliferation - Drug Effects
(4)
Cytokines
(4)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Abstract C117: Preclinical characterization of allogeneic CAR γδ T Cell therapy for prostate cancer targeting a novel dimeric epitope on PSMA

Expansion, Persistence and Pharmacodynamic Profile of ADI-001, a First-in-Class Allogeneic CD20-Targeted CAR Gamma Delta T Cell Therapy, in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma

684 Assay development and quantitative detection of ADI-001, a CD20-targeted γδ1 CAR T therapy, using AlloCell, a universal assay for monitoring of off-the-shelf allogeneic cell therapies

265 ADI-925: an allogeneic off-the-shelf chimeric adapter (CAd) γδ T cell therapy targeting NKG2D ligand-expressing cancers

246 Disruption of the cytokine signaling checkpoint CIS enhances serial-killing and anti-tumor activity of CAR-engineered γδ T cells

Correction: Profiling HPV-16–specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

203 Preclinical discovery and characterization of allogeneic anti-PSMA γδ CAR T therapy for prostate cancer

Clonally expanded B cells in multiple sclerosis bind EBV EBNA1 and GlialCAM

Allogeneic CD20‐targeted γδ T cells exhibit innate and adaptive antitumor activities in preclinical B‐cell lymphoma models

Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma

Correlations between macrophage/microglial activation marker sTREM-2 and measures of T-cell activation, neuroaxonal damage and disease severity in multiple sclerosis

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: (Trends in Molecular Medicine, 26:3 p:296-310, 2020)

Comprehensive Activation Profiling of Tabelecleucel, an Off-the-Shelf, Allogeneic EBV-Specific T-Cell Immunotherapy

ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19 CAR-T Therapy without the Need for Gene Editing

A Sensitive and Precise Universal Surveillance Solution for Pharmacokinetic Monitoring of Off-the-Shelf Cell Therapies

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies: Trends in Molecular Medicine, 26:3 p:296-310, 2020

Potent Activity of an Anti-ICAM1 Antibody-Drug Conjugate against Multiple Myeloma

ATA3219: A Potent Next-Generation Allogeneic Off-the-Shelf CD19-CAR T Therapy without the Need for Gene-Editing

98 ATA3271: an armored, next-generation off-the-shelf, allogeneic, mesothelin-CAR T cell therapy for solid tumors

Epstein-Barr virus-specific T cell therapy for progressive multiple sclerosis

Profiling HPV-16-specific T cell responses reveals broad antigen reactivities in oropharyngeal cancer patients

Cover Image

Toward “off‐the‐shelf” allogeneic CAR T cells

Transcriptional Landscape and TCR Diversity of ATA188, a Pre-manufactured, Allogeneic Epstein-Barr Virus-specific T-cell Immunotherapy for Patients with Multiple Sclerosis (MS) (4397)

Epstein–Barr Virus in Multiple Sclerosis: Theory and Emerging Immunotherapies

Suchergebnisse filtern